leisure time -WSS

leisure time

author：hotspot 2025-10-01 11:46:14 - browse：2

Two boxes of Ozempic stack on each other, while one lean on the stack tilted — health coverage from STAT — SEBASTIEN BOZON/AFP via Getty Images

Novo Nordisk’s Ozempic cut the risk of death in a trial of patients with type 2 diabetes and chronic kidney disease, suggesting it may offer some added benefits over other classes of drugs approved to treat this population.

Specifically, the diabetes drug cut the risk of cardiovascular-related deaths by 29% and all-cause deaths by 20%. Given the study parameters, this implies that over three years, 39 people would need to be treated to prevent one death from any cause, according to new results presented Friday at a meeting of the European Renal Association and published in the New England Journal of Medicine.

Ozempic also lowered the risk of major heart complications — including cardiovascular-related death, heart attack, or stroke — by 18%, driven primarily by the reduced rate of heart-linked death.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Readout Newsletter: Medeor's stem cell study, Moderna's stock dip

WSS

Brain injuries and the importance of a second opinion

Readout LOUD podcast: ESMO highlights & Roivant's big deal

Spinal cord stimulation reduces pain in amputees, study finds

SCOTUS to consider access to abortion pill mifepristone

Brain injuries and the importance of a second opinion

Roche to buy Carmot Therapeutics, developer of obesity drugs

entertainment

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

Supreme Court strikes down use of affirmative action

Patients' immediate access to test results puts radiologists in a bind

Medicare details structure of new drug price negotiation program

Prime Medicine says its gene editing passes test in monkeys

After affirmative action ruling, medical educators look to 'holistic review'

Bill would allow buprenorphine prescription for addiction via telehealth

Psychedelics group wrestles with new pharma identity

FDA needs staff influx to meet gene therapy needs, Marks says

After affirmative action ruling, medical educators look to 'holistic review'

CMS should re

Wikipedia

Supreme Court wrestles with OxyContin maker's bankruptcy deal

Teach medical students about patients with intellectual disabilities

AI models in health care face new federal disclosure requirements

After sickle

Life sciences investors close nearly $6 billion in new funds

In diabetes hearing, Sanders takes on a new foe: food makers

Wikipedia

knowledge

entertainment

explore